Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41375-023-01956-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pseudohyperkalemia in a Patient with Leukemia: A Diagnostic Pitfall in Emergency Medicine.
J Emerg Med
July 2025
Department of Emergency Medicine, Kinmen Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan.
Background: Pseudohyperkalemia is characterized by a falsely elevated serum potassium concentration, often due to cellular disruption during blood sample collection, processing, or transport. Accurate differentiation between pseudohyperkalemia and true hyperkalemia is vital to prevent inappropriate treatment, which can lead to iatrogenic hypokalemia.
Case Report: We present a case of a 67-year-old woman with hypertension and T-cell prolymphocytic leukemia who presented to the emergency department with fever and hypotension.
Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas.
Blood Adv
August 2025
University Medical Center Goettingen, Goettingen, Germany.
Mature T-cell leukemias and lymphomas (mTCL) comprise a clinically and genetically heterogeneous group of lymphoid malignancies. Most subtypes of peripheral T-cell lymphomas and leukemic T-cell malignancies show an aggressive clinical course and poor prognosis. Thus, these diseases urgently require novel therapeutic strategies.
View Article and Find Full Text PDFBlood- and bone marrow-based mature T-cell and natural killer cell leukemias and lymphomas: a summary in the series of the 2023 SH/EAHP Workshop.
Am J Clin Pathol
July 2025
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
This session included 51 cases submitted to the workshop "Progress in T- and NK-cell Lymphomas and Leukemias" by the Society for Hematopathology and European Association for Haematopathology under "Blood/Bone Marrow-Based Mature T- and NK-Cell Leukemias/Lymphomas" or "T/NK-cell neoplasms with a Leukemic Presentation." Entities encompassed T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia (LGLL), natural killer (NK)-LGLL/chronic lymphoproliferative disorder of NK cells, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, and their mimics. Submitted cases illustrated classic and variant morphology, immunophenotype, and clinical features; the overlaps with reactive T-cell /NK-cell lymphoproliferations; and challenges in differentiating these entities from other T-cell/NK-cell neoplasms with a leukemic presentation.
View Article and Find Full Text PDFLymphoid Malignancies in Ataxia-Telangiectasia: Experience with Novel Targeted Therapies.
Pediatr Blood Cancer
September 2025
Department of Pediatrics, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Patients with ataxia-telangiectasia (AT) face unique challenges in managing lymphoid malignancies due to heightened sensitivity to chemotherapy and radiation, requiring alternative treatment strategies. This report presents three cases demonstrating the successful integration of targeted therapies: ibrutinib for diffuse large B-cell lymphoma, alemtuzumab for T-cell prolymphocytic leukemia, and venetoclax for early T-cell precursor acute lymphoblastic leukemia. These cases highlight the potential of targeted agents to improve outcomes while minimizing toxicity.
View Article and Find Full Text PDFSingle-cell sequencing reveals shared clonal signatures in nonmalignant B and tumor cells in T-prolymphocytic leukemia.
Blood Neoplasia
May 2025
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
This study aimed to elucidate the clonal origin and evolutionary dynamics of T-cell prolymphocytic leukemia (T-PLL) using targeted next generation sequencing (NGS) of paired samples from diagnosis and relapse. DNA from both nonmalignant and tumor cells was extracted from sorted cell fractions obtained from 16 patients with T-PLL. NGS was performed using a customized Haloplex gene panel comprising 19 genes recurrently mutated in T-PLL ( and pathway).
View Article and Find Full Text PDF